ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Effect of levosimendan on plasma intestinal barrier factors in heart failure patients with reduced ejection fraction.
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesIn addition to dyspnea and edema, gastrointestinal discomfort is common among patients with heart failure (HF). Reduced cardiac output can lead to inadequate perfusion of the intestinal mucosa and subsequent impairment of the intestinal barrier. Levosimendan, a novel inotropic agent, binds to cardiac troponin C to enhance calcium sensitivity, activates ATP-dependent potassium channels in cardiomyocytes and vascular smooth muscle cells, exerts positive inotropic and vasodilatory effects, and reduces free radical generation, thereby improving systemic hemodynamics including intestinal circulation. However, clinical evidence regarding its protective effects on the intestinal barrier in HF patients remains limited, and the underlying mechanisms require further clarification. This study aims to investigate whether levosimendan confers protective effects on the intestinal barrier in HF patients and to explore its potential mechanisms.
methodsNetwork pharmacology was first used to analyze potential mechanisms of levosimendan in treating intestinal barrier dysfunction among HF patients. A total of 62 hospitalized patients with acute exacerbation of HF with reduced ejection fraction (HFrEF) were enrolled based on echocardiographic left ventricular ejection fraction. According to clinical medication regimens, patients were assigned to a conventional treatment group (
resultsNetwork pharmacology indicated that the effects of levosimendan on intestinal barrier dysfunction in HF patients may involve inflammation-related pathways such as IL-17 and TNF. Clinically, after treatment, zonulin decreased by 32.94 ng/mL in the levosimendan treatment group versus 15.05 ng/mL in the conventional treatment group (
conclusionsLevosimendan not only improves HF and gastrointestinal symptoms in hospitalized patients with acute exacerbation of HFrEF but also reduces plasma intestinal barrier factor levels. These effects may be associated with decreased plasma proinflammatory cytokines and increased anti-inflammatory cytokines after treatment, potentially involving IL-17 and TNF signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.